TScan Therapeutics (TCRX)

Its lead programmes include TSC-100 and TSC-101, which are being developed for patients with hematologic malignancies following hematopoietic stem cell transplantation. These candidates are designed to target residual leukemia cells and reduce the risk of relapse after transplant, a setting where disease recurrence remains a major clinical challenge. The company is also advancing TCR-T candidates for solid tumours, an area that is scientifically attractive but technically difficult because cancers can be heterogeneous and may evade immune recognition.

TScan describes itself as fully integrated, meaning it combines discovery, translational research, clinical development, and manufacturing-related capabilities within its operating model. Its platform is intended to support the selection of TCRs and targets across multiple cancer types, including multiplexed approaches that may address more than one tumour antigen. As a publicly traded biotech, TScan’s value is closely linked to clinical trial progress, safety data, regulatory milestones, financing needs, and the competitive landscape in engineered cell therapy.